Delaware § 2525 Testing, screening, and treatment of health conditions [Effective June 30, 2026]

Delaware Statutes

§ 2525 — Testing, screening, and treatment of health conditions [Effective June 30, 2026]

Delaware § 2525

Title24

Ch. 25Pharmacy [Effective until June 30, 2026].

Subch.Prescription Labeling; Exemptions [Effective June 30, 2026].

This text of Delaware § 2525 (Testing, screening, and treatment of health conditions [Effective June 30, 2026]) is published on Counsel Stack Legal Research, covering Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Del. Code tit. 24, § 2525 (2026).

Text

(a)Pursuant to a statewide written protocol approved by the Division of Public Health, a pharmacist may order, test, screen, and treat health conditions that include all of the following:

(1)Influenza.

(2)Group A streptococcus pharyngitis.

(3)SARS-COV-2 or other respiratory illness, condition, or disease.

(4)Lice.

(5)Skin conditions, including ringworm and athlete’s foot.

(6)Other emerging and existing public health threats identified by the Division of Public Health if permitted by an order, rule, or regulation.

(b)A pharmacist who orders, tests, screens, or treats health conditions under this section may use any test that may guide clinical decision making that is waived under the federal Clinical Laboratory Improvement Amendments of 1988 [42 U.S.C. § 263a], or the federal

Free access — add to your briefcase to read the full text and ask questions with AI

(a) Pursuant to a statewide written protocol approved by the Division of Public Health, a pharmacist may order, test, screen, and treat health conditions that include all of the following:

(1) Influenza.

(2) Group A streptococcus pharyngitis.

(3) SARS-COV-2 or other respiratory illness, condition, or disease.

(4) Lice.

(5) Skin conditions, including ringworm and athlete’s foot.

(6) Other emerging and existing public health threats identified by the Division of Public Health if permitted by an order, rule, or regulation.

(b) A pharmacist who orders, tests, screens, or treats health conditions under this section may use any test that may guide clinical decision making that is waived under the federal Clinical Laboratory Improvement Amendments of 1988 [42 U.S.C. § 263a], or the federal rules adopted thereunder, or any established screening procedure that is established via a statewide protocol.

(c) A pharmacist may delegate the administrative and technical tasks of performing a test waived by the federal Clinical Laboratory Improvement Amendments of 1988 to an intern or pharmacy technician acting under the supervision of the pharmacist.